Skip to main content
Katherine Look, MD, Obstetrics & Gynecology, Belvedere Tiburon, CA

KatherineYvonneLookMD

Obstetrics & Gynecology Belvedere Tiburon, CA

Gynecologic Oncology

Senior Medical Director Gyn Avastin Roche Genentech-RETIRED Dec 2016

Dr. Look is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Look's full profile

Already have an account?

  • Office

    4 Greenwood Cove Drive
    Apt E
    Belvedere Tiburon, CA 94920
    Phone+1 415-910-0548

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Gynecologic Oncology, 1983 - 1986
  • University of Illinois College of Medicine at Chicago
    University of Illinois College of Medicine at ChicagoResidency, Obstetrics and Gynecology, 1979 - 1983
  • University of Michigan Medical School
    University of Michigan Medical SchoolClass of 1979
  • Albion College
    Albion CollegeB.A., Biology/History, Magna Cum Laude, 1974

Awards, Honors, & Recognition

  • 1st Prize Resident Presentation CREOG and APGO Annual Meeting, 2004
  • Top Doctors for Women Coast to Coast Ladies Home Journal, 2002
  • Top Doctors - Gyn Oncology Castle Connelly, 2nd Edition, 2002
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • A phase I study of tasisulam (LY 573636), a novel anticancer compound, administered as as a 24-hour continuous infusion in patients with advanced solid tumors  
    Gordon MS, Ilaria R, De Alwis d, Mendelson DS, McKane S, Wagner MM, Look KY, Lorusso PM, Cancer Chemo Pharmacol, 1/1/2013
  • A phase II trial of Pemetrexed with Carboplatin in patients with Recurrent ovarian or primary peritoneal cancer  
    Sehouli, J, Alverez AM, Manouchhpour S, Ghatage P, Szczylik C, Zimmerman A, Bauknecht T, Look KY, Oskay-Ozcelik G, Gynecol Oncol, 1/1/2012
  • Phase II Evaluation of Capecitabine Patients with Refractory Non-Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study  
    Look KY, Blessing JA, Michener CM, Rubin SC, Ramirez PT, Int J Gyn Cancer, 1/1/2008
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • Phase II, single age arm study of tasisulam-sodium (LY573636) as 2nd-4th line therapy for platinum resistant ovarian cancer
    Gordon M, McMeeking Ds, Temkin s, Tew W, S Yapp, Scambia G, Streltsova O, Kaiser C, Ilaria R Look KY, AACRI-NCI-EORTC International conference: Molecular Targets and Cancer Therapeutics, 11/15/2009
  • Phase II, single age arm study of tasisulam-sodium (LY573636) as 2nd-4th line therapy for platinum resistant ovarian cancer
    Gordon M, McMeeking Ds, Temkin s, Tew W, S Yapp, Scambia G, Streltsova O, Kaiser C, Ilaria R Look KY, Molecular Cancer Therapeutics, 1/1/2009
  • A Phase I-II study of Pemetrexed in Combination with Platin Sensitive Recurrent Ovarian or Peritoneal Cancer (PSOC)
    Sehouli J, Kania M, Zimmerman A, Look K, Mustea A, ASCO, Chicago, IL, 5/30/2008
  • Join now to see all

Other

  • An Evidence-based Approach to adjuvant therapy for stage I-II endometrial cancer 
    Look KY, Reviews in Gynecologic Practice, Elsevier
    1/1/2002
  • New Developments in Ovary Cancer 
    Look KY, Intraperitoneal Chemo therapy Hoosier Oncology Group Vol. 3
    7/1/1990

Grant Support

  • Trial Of Tiazofurin And Allopurinol In Ovarian CarcinomaNational Cancer Institute1995–1996

Professional Memberships